Mass Spectrometry-Based Amyloid Typing in FFPE Biopsies: A Five-Year Prospective Experience from a Tertiary Academic Center in Spain
En palabras de los autores
Background: Accurate amyloid subtyping is essential for patient management but remains challenging with antibody-based methods. We prospectively evaluated a standardized LC-MS/MS workflow for routine amyloid typing, focusing on diagnostic yield, operational performance, and added value in cases not fully resolved by conventional methods. Methods: From 2020 to 2025, 115 FFPE biopsies from patients with suspected amyloidosis were analyzed at Hospital Universitario A Coruna, Spain, without laser microdissection. Proteins were identified and quantified using PEAKS, with a peak-area cutoff [≥]10 for candidate fibril proteins. Results: Seventy-nine cases (69%) were amyloid-positive, 22 (19%) negative and 14 (12%) indeterminate. AL (51%), ATTR (32%) and AA (10%) predominated, with additional AH (5%), mixed ATTR+AL, hereditary ATTRv and AIns amyloidoses. Binary concordance with conventional techniques ranged from 85.7% to 91.5%. LC-MS/MS provided additional diagnostic information in 64/110 evaluable cases (58.2%), including additional subtyping information in 53/110 (48.2%). The workflow also enabled relative quantification of variant versus wild-type TTR peptides and characterization of SAA post-translational modifications. Mean turnaround time was approximately two weeks and MS findings informed clinical management. Conclusions: LC-MS/MS amyloid typing was clinically feasible in routine FFPE biopsies without laser microdissection and supported identification of common, rare and mixed amyloid types.
Apareció: sábado, 24 de octubre. medRxiv. Preprint, todavía sin revisión por pares.